Anti-Campylobacter Probiotics: Latest Mechanistic Insights
Date
2022-07-29
Journal Title
Journal ISSN
Volume Title
Publisher
Mary Ann Liebert
Abstract
The Campylobacter genus is the leading cause of human gastroenteritis, with the consumption of contaminated
poultry meat as the main route of infection. Probiotic bacteria, such as Lactobacillus, Bacillus, Escherichia coli
Nissle, and Bifidobacterium species, have a great immunomodulatory capacity and exhibit antipathogenic
effects through various molecular mechanisms. Reducing Campylobacter levels in livestock animals, such as
poultry, will have a substantial benefit to humans as it will reduce disease transmissibility through the food
chain. Moreover, probiotic-based strategies might attenuate intestinal inflammatory processes, which consequently
reduce the severity of Campylobacter disease progression. At a molecular level, probiotics can also
negatively impact on the functionality of various Campylobacter virulence and survival factors (e.g., adhesion,
invasion), and on the associated colonization proteins involved in epithelial translocation. The current review
describes recent in vitro, in vivo, and preclinical findings on probiotic therapies, aiming to reduce Campylobacter
counts in poultry and reduce the pathogen’s virulence in the avian and human host. Moreover, we
focused in particular on probiotics with known anti-Campylobacter activity seeking to understand the biological
mechanisms involved in their mode of action.
Description
Publication history: Published online ahead of print - 29 July 2022.
item.page.type
Article
item.page.format
Keywords
probiotics, Campylobacter spp., mechanisms, poultry, humans
Citation
Balta,I., Butucel, E., Stef, L., Pet, I., Gradisteanu-Pircalabioru, G., Chifiriuc, C., Gundogdu, O., McCleery, D. and Corcionivoschi, N. (2022) 'Anti-Campylobacter Probiotics: Latest Mechanistic Insights', Foodborne Pathogens and Disease. Mary Ann Liebert. doI:10.1089/fpd.2022.0039